VERTANICAL is a globally leading biopharmaceutical company focused on the development of innovative therapies to treat of chronic pain. Our work is driven by a clear vision: A World of Chronic Pain. After over eight years of rigorous research and development, we have developed VER-01, a groundbreaking cannabinoid-based therapy for chronic pain. Our goal was to develop a pain medication that goes beyond purely analgesic (pain-relieving) effects but also provides significant benefits in treating common comorbid symptoms of chronic pain, such as sleep disorders and impaired physical function. Building on our success in the clinical development, we are pursuing the ambitious mission to set new standards in pain therapy and establish VER-01 as the leading therapy for chronic pain by 2030.